A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer.

Preclinical studies have shown that the vitamin D analogue EB 1089 has significantly less calcaemic activity than its parent compound 1,25-dihydroxyvitamin D (1,25(OH)2D3) and significant anti-tumour activity. This phase I trial was designed to evaluate the calcaemic effect of the drug in patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Gulliford, T., English, J., Colston, K. W., Menday, P., Moller, S., Coombes, R. C.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062933/
https://www.ncbi.nlm.nih.gov/pubmed/9662243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062933/
https://www.ncbi.nlm.nih.gov/pubmed/9662243

Ejemplares similares